Advertisement Almac - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More


Integrated Drug Development Solutions

October 23, 2017

Almac Group Announces Successful MHRA Inspection at Charnwood Facilities

- Almac Group, the Craigavon based global contract pharmaceutical development and manufacturing organisation, is pleased to announce the successful inspection...
pharmacuetical business review
October 23, 2017

Almac Pod™ – Changing the Global Dynamics of Temperature Controlled Shipping Solutions

Almac Group, the global contract development and manufacturing organisation, has recognised the need for a change in dynamics of temperature...
pharmacuetical business review



Almac provides research, development and delivery of pharmaceutical services worldwide.

The company offers a large range of integrated contract pharmaceutical development and manufacturing services ranging from research to commercialisation.

Pharmaceutical research, manufacturing and development services

Almac specialises in a wide range of pharmaceutical services, from diagnostics and pre-clinical biomarker discovery to companion diagnostic development and clinical test delivery. It performs these services at its clinical laboratory improvement amendments (CLIA) lab

Its active pharmaceutical ingredients (API) services and chemical development are suitable for all stages of drug development, including small molecules, potent and cytotoxic compounds and peptides

The company also provides pharmaceutical development for optimising clinical candidates and manufacturing drug product for all phases of clinical trial supply

Analytical and clinical services

Almac’s analytical services deliver comprehensive solutions supporting drug substance and product development programmes.

Its clinical services include designing and providing blinding, packaging and logistics services for global clinical trials; incorporating leading technologies; and efficient solutions through experienced supply chain management.

The company’s clinical technologies provide randomisation and trial supply management, electronic clinical outcome assessments (eCOA), patient alerts and reminders, data integration and biostatistical consulting services

Almac’s commercial services offer manufacturing and packaging solutions to support commercial product launches.

Support for all phases of drug development

Almac Group has experience in all phases of development, including pre-clinical, Phase I-IV, commercial and non-commercial

Global reach with local expertise

Almac Group is an international company that is privately owned and has organically grown for more than 40 years, employing in excess of 4,500 highly skilled personnel.

The company is headquartered in Craigavon, Northern Ireland, and has operations in Ireland, the US and Asia.

Almac Group’s global employee base ensures all projects are handled as effectively and efficiently as possible.

Almac combines global reach with local expertise to provide expert, innovative and high-quality service to more than 600 pharmaceutical and biotech companies worldwide.

Almac Group also offers expert global distribution capabilities, with 60 depots around the world, including China, India, Peru, Brazil, Mexico, Russia and Canada.

Diverse customer base

Almac Group understands each individual client’s needs are unique and prides itself on adapting its services.

The Group partners with a diverse customer base, including pharmaceutical, biotech, contract research organisations (CRO), academia and virtual organisations guaranteeing the stability of the company and building greater expertise and experience.

In addition, it possesses a wealth of experience across all therapeutic areas, including oncology, immunology, infectious diseases, pulmonary and respiratory diseases, gastroenterology, central nervous system and neurology.

Financial stability

Almac Group is a financially stable company with no venture capital investment and is committed to the long term development and growth of the organisation. All profit is reinvested into the business to continually improve its innovation, technology, capabilities and people. Group turnover is currently $½ billion and is experience consistent growth year on year.


The Almac Group’s vision clearly positions the organisation within the industry, aiming to be a leader in the generation of superior solutions for the advancement of human health.

Core values

The company’s core values define Almac’s fundamental set of principles and beliefs, focusing on:

•   Outstanding quality

•   Inspirational people

•   Superlative customer focus

•   Exceptional innovation

•   Sustainable financial performance


UK (Global Headquarters)
Almac House
20 Seagoe Industrial Estate
BT63 5QD
United Kingdom

T: +44 (0) 283 833 2200
F: +44 (0) 283 833 2299

Clinical Services

Almac designs and provides blinding, packaging and logistics services for global clinical trials, incorporating leading technologies and efficient solutions through the most experienced supply chain management in the marketplace. Commercial drug procurement Almac provides an end-to-end global commercial drug procurement service and has experience across all major clinical trial markets, product types and assurance of…

Clinical Technologies

Almac has been providing interactive voice recognition (IVR) and interactive web response (IWR) technologies since 1995. Through its industry-leading IXRS®2.0 integrated IVR / IWR technology, the company offers flexible solutions for patient enrolment, screening, randomisation, drug assignment, inventory management, patient compliance, electronic patient-reported outcomes, and adaptive trials. Almac's experienced teams help clients streamline research and…

Commercial Services

Ensuring a simple technology transfer process, Almac offers integrated commercial services for all drug products from active pharmaceutical ingredient (API) supply, manufacturing, testing and packaging to end-user distribution. Specialising in the manufacture and primary packaging of solid oral dosage forms and with a wide range of packaging technologies, the company also provides customised secondary labelling…

Biomarker Discovery and Development

Almac provides a wide range of biomarker solutions ranging from pre-clinical biomarker discovery to biomarker trial management, full companion diagnostic development and clinical test delivery from its clinical laboratory improvement amendments (CLIA) laboratory. The company has a portfolio of proprietary discovery arrays and extensive experience and expertise working with formalin fixed paraffin embedded (FFPE) tissue.…

Pharmaceutical Development

Almac’s team of highly skilled scientists can develop your clinical candidate into an optimum formulation, and manufacture drug product for all phases of clinical trial supply (Phase 0 – IV). With customised, in-house engineered containment solutions, the company can develop and manufacture batches of solid, oral dose drug product containing potent active pharmaceutical ingredients (API)…

API Services and Chemical Development

Almac provides services for all stages of drug development for small molecules, potent and cytotoxic compounds and peptides. Its services include active pharmaceutical ingredient (API) supply, drug product development, stable and radiolabelling, solid state services and biocatalysis. Almac also offers rapidd™, an integrated package that supports candidates from pre-clinical development to Phase I regulatory submission.…
Quick Contact Almac
Quick Contact Almac

RCSI and Almac Discovery Enter Research Collaboration

The Royal College of Surgeons (RCSI) in Ireland and Almac Discovery have announced a major research collaboration that aims to...
13th February 2017

Almac Group Expands Commercial Capabilities

Almac Group is pleased to announce that it has expanded its Medicines and Healthcare Products Regulatory Agency (MHRA) / US...
14th November 2016

Almac Group Announce £27m Global Expansion

Almac Group is excited to announce ambitious plans to expand its operations in Europe and North America increasing its global...
9th November 2016

Almac Group Supports Amicus Therapeutics’ Orphan Drug Product

Almac Group wishes to congratulate its long-term client partner Amicus Therapeutics on receiving the European approval of its first orphan...
10th August 2016
Quick Contact Almac

Quick Contact Almac
Quick Contact Almac
Quick Contact Almac

Contact Almac

Optional Data

Almost there, complete this form and hit the submit button to complete your registration.


Finally, complete a quick security check and confirm terms and conditions:

Quick Contact Almac